When was Rezolute founded?

Rezolute was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is Rezolute located?

Rezolute is headquartered in Denver, United States.

Who is the current CEO of Rezolute?

Nevan Charles Elam of Rezolute. They have also founded 1 company.

How many employees does Rezolute have?

As of Aug 31, 2026, the latest employee count at Rezolute is 75.

Is Rezolute a funded company?

Rezolute is a funded company, having raised an undisclosed amount across 21 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Aug 07, 2012.

When was the latest funding round of Rezolute?

Rezolute's latest funding was a $***** Post IPO round on Oct 09, 2020, with participation from 4 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.48B in funding in 2026 to date.

Where does Rezolute rank among its competitors?

Rezolute ranks 93rd amongst 3990 active competitors, of which 1318 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Rezolute?

Rezolute's top competitors include BridgeBio, Jazz Pharmaceuticals and BeiGene. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Rezolute - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI). The company is a late-stage biopharmaceutical company dedicated to addressing serious unmet needs in rare diseases. It is focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Their antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor HI. The company is committed to developing medicines and working with partners to fight hyperinsulinism in all its forms. They are enrolling Phase III sunRIZE trial in the study of congenital hyperinsulinism. The company is focused on drug development for patients with rare diseases in multiple therapeutic areas.

Website: rezolutebio.com
Social
Email ID: *****@rezolutebio.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2012

Location

Denver, United States

Stage

Public

Latest Funding Round

Post IPO, Oct 09, 2020, $*****

Investors

BVF Partners & 9 more

Ranked

93^rd among 3990 active competitors

Employee Count

75 as on Aug 31, 2026

Investment & Acquisitions

XOMA Corporation

Similar Companies

BridgeBio & 3811 more

Exit Details

Public

View Rezolute's full profile

Rezolute is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Rezolute, Inc. CIN: 27-3440894 , United States, Active	Dec 31, 2011	-	51 (As on Jun 30, 2023)	-

Rezolute got listed on May 08, 2012.

Click here to take a look at Rezolute's IPO in detail

Rezolute has raised funding over 21 rounds. Its first funding round was on Aug 07, 2012. Its latest funding round was a Post IPO round on Oct 09, 2020 for $*****. 4 investors participated in its latest round. Rezolute has 10 institutional investors.

Here is the list of recent funding rounds of Rezolute:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 09, 2020	2070953	Post IPO	1752478	2397470	3940499	8596072
Jul 24, 2019	1597771	Post IPO	6770568	2386530	7574534	Handok & 1 more
Apr 03, 2018	5852550	Post IPO	3323471	4163785	9446293	BVF Partners

Access funding benchmarks and valuations. Sign up today!

View details of Rezolute's funding rounds and investors

The founders of Rezolute are Nevan Charles Elam and Hoyoung Huh. Nevan Charles Elam is the CEO of Rezolute.

Here are the details of Rezolute's key team members:

Nevan Charles Elam: Co-Founder & CEO of Rezolute and founder of 1 other company.
Contact Info: 1 email address
Hoyoung Huh: Co-Founder of Rezolute and founder of 1 other company.

View details of Rezolute's Founder profiles and Board Members

Rezolute's employee count trend

Rezolute has 75 employees as of Aug 26. Here is Rezolute's employee count trend over the years:

Uncover Rezolute's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rezolute include BridgeBio, Jazz Pharmaceuticals and BeiGene. Here is the list of Top 10 competitors of Rezolute, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
4th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
5th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
6th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
7th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
8th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
9th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
10th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
93rd	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	64/100